Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Promega Corporation

Approvalsnew device approved (PMA)15 Sept 2026

Promega Corporation

15 Sept 2026: New device approved (PMA) · OncoMate® MSI Dx Analysis System. Recorded in the openFDA device PMA data.

View the source record

Decided
15 Sept 2026
Device
OncoMate® MSI Dx Analysis System
Specialty
Medical Genetics
Type
Original approval
Reference
P250046
Location
Madison, WI
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Promega Corporation

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.